Head of R&D Robert Lenz to leave Neumora

Neumora Therapeutics Inc. (NASDAQ:NMRA) said EVP and Head of R&D Robert Lenz is leaving the company. His exit comes about two weeks after the departure of President and CEO Henry Gosebruch, both in the wake of KOR antagonist navacaprant’s failure in the Phase III KOASTAL-1 study to treat depression.

Along with Monday’s news of Lenz’s departure, Neumora said it is pausing two other studies of navacaprant, KOASTAL-2 and KOASTAL-3, to implement changes in site selection, medical monitoring and patient screening, with the goal of optimizing them for success. Neumora is also stopping a Phase II trial of navacaprant to treat bipolar depression...